Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 423

1.

Maternal Cardiovascular Dysregulation During Early Pregnancy After In Vitro Fertilization Cycles in the Absence of a Corpus Luteum.

Conrad KP, Petersen JW, Chi YY, Zhai X, Li M, Chiu KH, Liu J, Lingis MD, Williams RS, Rhoton-Vlasak A, Larocca JJ, Nichols WW, Segal MS.

Hypertension. 2019 Sep;74(3):705-715. doi: 10.1161/HYPERTENSIONAHA.119.13015. Epub 2019 Jul 29.

PMID:
31352818
2.

Letter by Mäki-Petäjä et al Regarding Article "Elevated Muscle Sympathetic Nerve Activity Contributes to Central Artery Stiffness in Young and Middle-Age/Older Adults".

Mäki-Petäjä KM, Wilkinson IB, Nichols WW.

Hypertension. 2019 Aug;74(2):e31-e32. doi: 10.1161/HYPERTENSIONAHA.119.13292. Epub 2019 Jun 24. No abstract available.

PMID:
31230544
3.

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.

Das S, Li J, Riccobene T, Carrothers TJ, Newell P, Melnick D, Critchley IA, Stone GG, Nichols WW.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02187-18. doi: 10.1128/AAC.02187-18. Print 2019 Apr. Review.

PMID:
30670413
4.

Increased Preeclampsia Risk and Reduced Aortic Compliance With In Vitro Fertilization Cycles in the Absence of a Corpus Luteum.

von Versen-Höynck F, Schaub AM, Chi YY, Chiu KH, Liu J, Lingis M, Stan Williams R, Rhoton-Vlasak A, Nichols WW, Fleischmann RR, Zhang W, Winn VD, Segal MS, Conrad KP, Baker VL.

Hypertension. 2019 Mar;73(3):640-649. doi: 10.1161/HYPERTENSIONAHA.118.12043.

PMID:
30636552
5.

Wave reflections and global arterial compliance during normal human pregnancy.

Rodriguez C, Chi YY, Chiu KH, Zhai X, Lingis M, Williams RS, Rhoton-Vlasak A, Nichols WW, Petersen JW, Segal MS, Conrad KP, Mohandas R.

Physiol Rep. 2018 Dec;6(24):e13947. doi: 10.14814/phy2.13947.

6.

A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa.

Sy SKB, Zhuang L, Xia H, Schuck VJ, Nichols WW, Derendorf H.

Clin Microbiol Infect. 2019 Jul;25(7):904.e9-904.e16. doi: 10.1016/j.cmi.2018.10.014. Epub 2018 Oct 28.

PMID:
30394361
7.

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.

Livermore DM, Mushtaq S, Doumith M, Jamrozy D, Nichols WW, Woodford N.

J Antimicrob Chemother. 2018 Dec 1;73(12):3336-3345. doi: 10.1093/jac/dky363.

PMID:
30247546
8.

Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.

Chalhoub H, Sáenz Y, Nichols WW, Tulkens PM, Van Bambeke F.

Int J Antimicrob Agents. 2018 Nov;52(5):697-701. doi: 10.1016/j.ijantimicag.2018.07.027. Epub 2018 Aug 3.

PMID:
30081137
9.

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.

Nichols WW, Stone GG, Newell P, Broadhurst H, Wardman A, MacPherson M, Yates K, Riccobene T, Critchley IA, Das S.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e02590-17. doi: 10.1128/AAC.02590-17. Print 2018 Nov.

10.

Application of Arterial Hemodynamics to Clinical Practice: A Testament to Medical Science in London.

O'Rourke M, Adji A, Nichols WW, Vlachopoulos C, Edelman ER.

Artery Res. 2017 Jun;18:81-86. doi: 10.1016/j.artres.2017.03.003. No abstract available.

11.

Avibactam Pharmacokinetic/Pharmacodynamic Targets.

Nichols WW, Newell P, Critchley IA, Riccobene T, Das S.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02446-17. doi: 10.1128/AAC.02446-17. Print 2018 Jun. Review.

12.

A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa.

Sy SKB, Zhuang L, Xia H, Beaudoin ME, Schuck VJ, Nichols WW, Derendorf H.

J Antimicrob Chemother. 2018 May 1;73(5):1295-1304. doi: 10.1093/jac/dkx537.

PMID:
29415212
13.

Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2.

Sleger T, Gangl E, Pop-Damkov P, Krause KM, Laud PJ, Slee AM, Nichols WW.

J Chemother. 2018 Apr;30(2):95-100. doi: 10.1080/1120009X.2017.1405609. Epub 2017 Nov 30.

14.

AmpC β-lactamase induction by avibactam and relebactam.

Livermore DM, Jamrozy D, Mushtaq S, Nichols WW, Young K, Woodford N.

J Antimicrob Chemother. 2017 Dec 1;72(12):3342-3348. doi: 10.1093/jac/dkx298.

PMID:
28962008
15.

Modeling the Kinetics of the Permeation of Antibacterial Agents into Growing Bacteria and Its Interplay with Efflux.

Nichols WW.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e02576-16. doi: 10.1128/AAC.02576-16. Print 2017 Oct.

16.

The in vitro activity of ceftazidime-avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in São Paulo, Brazil.

Rossi F, Cury AP, Franco MRG, Testa R, Nichols WW.

Braz J Infect Dis. 2017 Sep - Oct;21(5):569-573. doi: 10.1016/j.bjid.2017.03.008. Epub 2017 Apr 20. No abstract available.

17.

Reply.

Papaioannou TG, Karageorgopoulou TD, Sergentanis TN, Protogerou AD, Psaltopoulou T, Sharman JE, Weber T, Blacher J, Daskalopoulou SS, Wassertheurer S, Khir AW, Vlachopoulos C, Stergiopulos N, Stefanadis C, Nichols WW, Tousoulis D.

J Hypertens. 2017 Apr;35(4):894-896. doi: 10.1097/HJH.0000000000001247. No abstract available.

PMID:
28248906
18.

Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations.

McLeod SM, Patey SA, Huband MD, Nichols WW.

Int J Antimicrob Agents. 2017 Apr;49(4):437-442. doi: 10.1016/j.ijantimicag.2016.12.011. Epub 2017 Feb 24.

PMID:
28242258
19.

All-Extremity Exercise Training Improves Arterial Stiffness in Older Adults.

Kim HK, Hwang CL, Yoo JK, Hwang MH, Handberg EM, Petersen JW, Nichols WW, Sofianos S, Christou DD.

Med Sci Sports Exerc. 2017 Jul;49(7):1404-1411. doi: 10.1249/MSS.0000000000001229.

20.

Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa.

Buyck JM, Luyckx C, Muccioli GG, Krause KM, Nichols WW, Tulkens PM, Van Bambeke F.

J Antimicrob Chemother. 2017 May 1;72(5):1400-1409. doi: 10.1093/jac/dkw587.

PMID:
28137941
21.

Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.

Sy SK, Zhuang L, Beaudoin ME, Kircher P, Tabosa MA, Cavalcanti NC, Grunwitz C, Pieper S, Schuck VJ, Nichols WW, Derendorf H.

J Antimicrob Chemother. 2017 Apr 1;72(4):1109-1117. doi: 10.1093/jac/dkw535.

PMID:
28077672
22.

Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.

Lahiri SD, Bradford PA, Nichols WW, Alm RA.

J Antimicrob Chemother. 2016 Oct;71(10):2848-55. doi: 10.1093/jac/dkw248. Epub 2016 Jul 7.

PMID:
27402011
23.

Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.

Giani T, Cannatelli A, Di Pilato V, Testa R, Nichols WW, Rossolini GM.

Diagn Microbiol Infect Dis. 2016 Sep;86(1):83-5. doi: 10.1016/j.diagmicrobio.2016.03.002. Epub 2016 Mar 2.

PMID:
27394638
24.

Influence of the central-to-peripheral arterial stiffness gradient on the timing and amplitude of wave reflections.

Hickson SS, Nichols WW, Yasmin, McDonnell BJ, Cockcroft JR, Wilkinson IB, McEniery CM.

Hypertens Res. 2016 Oct;39(10):723-729. doi: 10.1038/hr.2016.64. Epub 2016 Jun 16.

25.

The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.

Pillar CM, Stoneburner A, Shinabarger DL, Krause KM, Nichols WW.

Lett Appl Microbiol. 2016 Aug;63(2):96-102. doi: 10.1111/lam.12592.

26.

In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).

Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4743-9. doi: 10.1128/AAC.00220-16. Print 2016 Aug.

27.

Accuracy of commercial devices and methods for noninvasive estimation of aortic systolic blood pressure a systematic review and meta-analysis of invasive validation studies.

Papaioannou TG, Karageorgopoulou TD, Sergentanis TN, Protogerou AD, Psaltopoulou T, Sharman JE, Weber T, Blacher J, Daskalopoulou SS, Wassertheurer S, Khir AW, Vlachopoulos C, Stergiopulos N, Stefanadis C, Nichols WW, Tousoulis D.

J Hypertens. 2016 Jul;34(7):1237-48. doi: 10.1097/HJH.0000000000000921. Review.

PMID:
27136312
28.

Nitrates in Heart Failure with Preserved Ejection Fraction.

O'Rourke MF, Safar ME, Nichols WW.

N Engl J Med. 2016 Apr 21;374(16):1587-8. doi: 10.1056/NEJMc1601507. No abstract available.

PMID:
27096586
29.

Response to Budoff and Steigerwalt.

Townsend RR, Rosendorff C, Nichols WW, Edwards DG, Chirinos JA, Fernhall B, Cushman WC.

J Am Soc Hypertens. 2016 May;10(5):470-1. doi: 10.1016/j.jash.2016.03.181. Epub 2016 Mar 23. No abstract available.

PMID:
27085206
30.

In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).

de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3163-9. doi: 10.1128/AAC.03042-15. Print 2016 May.

31.

In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.

Flamm RK, Nichols WW, Sader HS, Farrell DJ, Jones RN.

Int J Antimicrob Agents. 2016 Mar;47(3):235-42. doi: 10.1016/j.ijantimicag.2016.01.004. Epub 2016 Feb 3.

PMID:
26920105
32.
33.

β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.

Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK, Jones RN.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1328-35. doi: 10.1128/AAC.01173-15.

34.

Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam.

Pagès JM, Peslier S, Keating TA, Lavigne JP, Nichols WW.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1349-59. doi: 10.1128/AAC.01585-15.

35.

American Society of Hypertension position paper: central blood pressure waveforms in health and disease.

Townsend RR, Rosendorff C, Nichols WW, Edwards DG, Chirinos JA, Fernhall B, Cushman WC.

J Am Soc Hypertens. 2016 Jan;10(1):22-33. doi: 10.1016/j.jash.2015.10.012. Epub 2015 Nov 5.

PMID:
26612106
36.

Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria.

Asli A, Brouillette E, Krause KM, Nichols WW, Malouin F.

Antimicrob Agents Chemother. 2015 Nov 16;60(2):752-6. doi: 10.1128/AAC.02102-15. Print 2016 Feb.

37.

Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.

Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Schuck VJ, Nichols WW, Mouton JW.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):368-75. doi: 10.1128/AAC.01269-15. Print 2016 Jan.

38.

High Flow Velocity and Low Systolic Pressure: Compliance of the Aortic Wall or Venturi Effect Within.

O'Rourke MF, Nichols WW.

J Am Coll Cardiol. 2015 Aug 4;66(5):595-6. doi: 10.1016/j.jacc.2015.04.077. No abstract available.

39.

Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association.

Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, Heffernan KS, Lakatta EG, McEniery CM, Mitchell GF, Najjar SS, Nichols WW, Urbina EM, Weber T; American Heart Association Council on Hypertension.

Hypertension. 2015 Sep;66(3):698-722. doi: 10.1161/HYP.0000000000000033. Epub 2015 Jul 9. No abstract available.

40.

In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.

Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, Woodford N.

Antimicrob Agents Chemother. 2015 Sep;59(9):5324-30. doi: 10.1128/AAC.00678-15. Epub 2015 Jun 22.

41.

In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible Gram-negative clinical isolates obtained from patients in Canadian hospitals.

Denisuik AJ, Karlowsky JA, Denisuik T, Nichols WW, Keating TA, Adam HJ, Baxter M, Walkty A, Zhanel GG.

Antimicrob Agents Chemother. 2015;59(6):3623-6. doi: 10.1128/AAC.00364-15. Epub 2015 Mar 30.

42.

Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa.

Pitart C, Marco F, Keating TA, Nichols WW, Vila J.

Antimicrob Agents Chemother. 2015;59(6):3059-65. doi: 10.1128/AAC.05136-14. Epub 2015 Mar 9.

43.

In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.

Testa R, Cantón R, Giani T, Morosini MI, Nichols WW, Seifert H, Stefanik D, Rossolini GM, Nordmann P.

Int J Antimicrob Agents. 2015 Jun;45(6):641-6. doi: 10.1016/j.ijantimicag.2014.12.033. Epub 2015 Feb 17.

PMID:
25748553
44.

Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.

Papp-Wallace KM, Bajaksouzian S, Abdelhamed AM, Foster AN, Winkler ML, Gatta JA, Nichols WW, Testa R, Bonomo RA, Jacobs MR.

Diagn Microbiol Infect Dis. 2015 May;82(1):65-9. doi: 10.1016/j.diagmicrobio.2015.02.003. Epub 2015 Feb 14.

45.

Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.

Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Nichols WW, Mouton JW.

Antimicrob Agents Chemother. 2015 Apr;59(4):2299-304. doi: 10.1128/AAC.04627-14. Epub 2015 Feb 2.

46.

In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.

Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K.

Antimicrob Agents Chemother. 2015 Mar;59(3):1789-93. doi: 10.1128/AAC.04191-14. Epub 2014 Dec 22.

47.

In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.

Berkhout J, Melchers MJ, van Mil AC, Nichols WW, Mouton JW.

Antimicrob Agents Chemother. 2015 Feb;59(2):1138-44. doi: 10.1128/AAC.04146-14. Epub 2014 Dec 8.

48.

In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.

Yoshizumi A, Ishii Y, Aoki K, Testa R, Nichols WW, Tateda K.

J Infect Chemother. 2015 Feb;21(2):148-51. doi: 10.1016/j.jiac.2014.08.028. Epub 2014 Oct 25.

PMID:
25444674
49.

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes.

Dallow J, Otterson LG, Huband MD, Krause KM, Nichols WW.

Int J Antimicrob Agents. 2014 Dec;44(6):552-6. doi: 10.1016/j.ijantimicag.2014.07.023. Epub 2014 Sep 16.

PMID:
25293578
50.

In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.

MacVane SH, Crandon JL, Nichols WW, Nicolau DP.

Antimicrob Agents Chemother. 2014 Nov;58(11):6913-9. doi: 10.1128/AAC.03267-14. Epub 2014 Sep 15.

Supplemental Content

Loading ...
Support Center